cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.6337992
title: Dataset related to the article "Endomyocardial Biopsy: The Forgotten Piece in the Arrhythmogenic Cardiomyopathy Puzzle"

description: This record contains raw data related to the article "Endomyocardial Biopsy: The Forgotten Piece in the Arrhythmogenic Cardiomyopathy Puzzle" <em><strong>Abstract</strong></em> Background Endomyocardial biopsy (EMB) is part of 2010 Task Force Criteria (TFC) for arrhythmogenic right ventricular cardiomyopathy (ARVC). However, its usage has been curtailed because of its low presumed diagnostic yield, and it is now a poorly used tool. This study aims to analyze the contribution of EMB to the final diagnosis of ARVC. Methods and Results We included 104 consecutive patients evaluated for a suspicion of ARVC, who were referred for EMB. Patients with suspected left dominant pattern were excluded from the primary analysis. Subjects were initially stratified according to TFC without considering EMB. After EMB, patients were reclassified accordingly, and the reclassification rate was calculated. EMB yielded a diagnostic finding in 92 patients (85.5%). After including EMB evaluation, 20 (43%) more patients "at risk" received a definite diagnosis of ARVC. Overall, 59 patients received a definite diagnosis of ARVC, 34% only after EMB. EMB appeared to be the better-performing exam with respect to the final diagnosis (β, 2.2; area uder the curve, 0.73; <em>P</em>&lt;0.05). The reclassification improvement after EMB measured 28%. TFC score increased from 3.5±1.3 to 4.3±1.4 (<em>P</em>&lt;0.001). Notably, active inflammation was present in 6 (10%) patients. Minor complications were reported in only 2% of the cohort. In patients with suspected left-dominant disease, conventional TFC performed poorly. Conclusions Electroanatomic voltage mapping-guided EMB was safe and yielded an optimal diagnostic yield. It allowed upgrading of the diagnosis of nearly one-third of the patients considered "at risk." Classical TFC without EMB performed poorly in patients with the left dominant form of ARVC.
DOI: 10.5281/zenodo.6337898
title: Dataset related to the article "Long-Term Outcomes of Near-Zero Radiation Ablation of Paroxysmal Supraventricular Tachycardia: A Comparison With Fluoroscopy-Guided Approach"

description: This record contains raw data related to the article "Long-Term Outcomes of Near-Zero Radiation Ablation of Paroxysmal Supraventricular Tachycardia: A Comparison With Fluoroscopy-Guided Approach". <em><strong>Abstract</strong></em> <strong>Objectives: </strong>This study aimed to assess the long-term outcomes of minimally fluoroscopic approach (MFA) compared with conventional fluoroscopic ablation (ConvA) in terms of recurrences of arrhythmia and long-term complications. <strong>Background: </strong>Catheter ablation (CA) of supraventricular tachycardia (SVT) with an MFA, under the guidance of electroanatomic mapping (EAM) systems, results in a significant reduction in exposure to ionizing radiations without impairing acute procedural success and complication rate. However, data regarding long-term outcomes of MFA compared with ConvA are lacking. <strong>Methods: </strong>This is a retrospective observational study. All patients undergoing MFA CA of SVT (atrioventricular nodal re-entrant tachycardia and atrioventricular re-entrant tachycardia) between 2010 and 2015 were enrolled and were compared with matched subjects (1 MFA: 2 ConvA) undergoing ConvA during the same period. The 2 co-primary outcomes were recurrence of arrhythmias and long-term complications. <strong>Results: </strong>A total of 618 patients (mean age 38 ± 15 years, 60% female) were enrolled. MFA included 206 patients, whereas 412 were treated with ConvA. Acute success (99% vs. 97%; p = 0.10) and acute complications (2.4% vs. 5.3%; p = 0.14) were similar in the 2 groups. During a median follow-up of 4.4 years, 5.9% of patients experienced recurrence of arrhythmias. At multivariate analysis, ConvA (hazard ratio [HR]: 3.03) and procedural success (HR: 0.10) were independently associated with recurrence of arrhythmias. Late complications (i.e., advance atrioventricular block and need for pacemaker implantation) occurred more frequently in ConvA (3.4% vs. 0.5%; p = 0.03) compared with MFA. <strong>Conclusions: </strong>CA guided by EAM systems with MFA provided better long-term results and reduced risk of complications compared with ConvA.
DOI: 10.5281/zenodo.6337897
title: Dataset related to the article "Long-Term Outcomes of Near-Zero Radiation Ablation of Paroxysmal Supraventricular Tachycardia: A Comparison With Fluoroscopy-Guided Approach"

description: This record contains raw data related to the article "Long-Term Outcomes of Near-Zero Radiation Ablation of Paroxysmal Supraventricular Tachycardia: A Comparison With Fluoroscopy-Guided Approach". <em><strong>Abstract</strong></em> <strong>Objectives: </strong>This study aimed to assess the long-term outcomes of minimally fluoroscopic approach (MFA) compared with conventional fluoroscopic ablation (ConvA) in terms of recurrences of arrhythmia and long-term complications. <strong>Background: </strong>Catheter ablation (CA) of supraventricular tachycardia (SVT) with an MFA, under the guidance of electroanatomic mapping (EAM) systems, results in a significant reduction in exposure to ionizing radiations without impairing acute procedural success and complication rate. However, data regarding long-term outcomes of MFA compared with ConvA are lacking. <strong>Methods: </strong>This is a retrospective observational study. All patients undergoing MFA CA of SVT (atrioventricular nodal re-entrant tachycardia and atrioventricular re-entrant tachycardia) between 2010 and 2015 were enrolled and were compared with matched subjects (1 MFA: 2 ConvA) undergoing ConvA during the same period. The 2 co-primary outcomes were recurrence of arrhythmias and long-term complications. <strong>Results: </strong>A total of 618 patients (mean age 38 ± 15 years, 60% female) were enrolled. MFA included 206 patients, whereas 412 were treated with ConvA. Acute success (99% vs. 97%; p = 0.10) and acute complications (2.4% vs. 5.3%; p = 0.14) were similar in the 2 groups. During a median follow-up of 4.4 years, 5.9% of patients experienced recurrence of arrhythmias. At multivariate analysis, ConvA (hazard ratio [HR]: 3.03) and procedural success (HR: 0.10) were independently associated with recurrence of arrhythmias. Late complications (i.e., advance atrioventricular block and need for pacemaker implantation) occurred more frequently in ConvA (3.4% vs. 0.5%; p = 0.03) compared with MFA. <strong>Conclusions: </strong>CA guided by EAM systems with MFA provided better long-term results and reduced risk of complications compared with ConvA.
DOI: 10.5281/zenodo.6337868
title: Dataset related to the article "Prior myocarditis and ventricular arrhythmias: The importance of scar pattern"

description: This record contains raw data related to the article "Prior myocarditis and ventricular arrhythmias: The importance of scar pattern". <em><strong>Abstract</strong></em> <strong>Background: </strong>Multiple studies have addressed the importance of anteroseptal scar in patients with nonischemic cardiomyopathy. However, this pattern has never been fully evaluated in patients with prior myocarditis. <strong>Objective: </strong>The purpose of this study was to evaluate whether anteroseptal scar is associated with worse outcome in patients with prior myocarditis and how it affects the efficacy of catheter ablation (CA). <strong>Methods: </strong>This was a retrospective study of consecutive patients with prior myocarditis and arrhythmic presentation. Cardiac magnetic resonance and electroanatomic voltage mapping were used to identify the scar pattern. Patients were referred for either CA or escalated antiarrhythmic drug (AAD) therapy. The main outcome was ventricular arrhythmia (VA)-free survival according to the presence of anteroseptal scar. <strong>Results: </strong>A total of 144 consecutive patients with prior myocarditis were included. Mean age was 42.1 ± 14.9 years, and 58% were men. Ejection fraction was normal in 73% of patients. Anteroseptal scar was present in 44% of cases. Sixty-one patients (42%) underwent CA. Overall, at 2-year follow-up, VA-free survival was 77% in the CA group. After CA, the mean number of AADs taken by each patient decreased from 1.8 to 0.9 per day (p&lt;0.001). The presence of anteroseptal scar was found to be an independent predictor of VA relapse both in patients treated with CA (hazard ratio [HR] 3.6; 95% confidence interval [CI] 1.1-11.4; P = .03) and in the overall population (HR 2.0; 95% CI 1.2-3.5; P = .02) . <strong>Conclusion: </strong>In patients with prior myocarditis and VA, the presence of anteroseptal scar negatively predicts outcomes irrespective of treatment strategy.
DOI: 10.5281/zenodo.6337867
title: Dataset related to the article "Prior myocarditis and ventricular arrhythmias: The importance of scar pattern"

description: This record contains raw data related to the article "Prior myocarditis and ventricular arrhythmias: The importance of scar pattern". <em><strong>Abstract</strong></em> <strong>Background: </strong>Multiple studies have addressed the importance of anteroseptal scar in patients with nonischemic cardiomyopathy. However, this pattern has never been fully evaluated in patients with prior myocarditis. <strong>Objective: </strong>The purpose of this study was to evaluate whether anteroseptal scar is associated with worse outcome in patients with prior myocarditis and how it affects the efficacy of catheter ablation (CA). <strong>Methods: </strong>This was a retrospective study of consecutive patients with prior myocarditis and arrhythmic presentation. Cardiac magnetic resonance and electroanatomic voltage mapping were used to identify the scar pattern. Patients were referred for either CA or escalated antiarrhythmic drug (AAD) therapy. The main outcome was ventricular arrhythmia (VA)-free survival according to the presence of anteroseptal scar. <strong>Results: </strong>A total of 144 consecutive patients with prior myocarditis were included. Mean age was 42.1 ± 14.9 years, and 58% were men. Ejection fraction was normal in 73% of patients. Anteroseptal scar was present in 44% of cases. Sixty-one patients (42%) underwent CA. Overall, at 2-year follow-up, VA-free survival was 77% in the CA group. After CA, the mean number of AADs taken by each patient decreased from 1.8 to 0.9 per day (p&lt;0.001). The presence of anteroseptal scar was found to be an independent predictor of VA relapse both in patients treated with CA (hazard ratio [HR] 3.6; 95% confidence interval [CI] 1.1-11.4; P = .03) and in the overall population (HR 2.0; 95% CI 1.2-3.5; P = .02) . <strong>Conclusion: </strong>In patients with prior myocarditis and VA, the presence of anteroseptal scar negatively predicts outcomes irrespective of treatment strategy.
DOI: 10.5281/zenodo.6337831
title: Dataset related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients"

description: This record contains raw data related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients" <em><strong>Abstract</strong></em> <strong>Background: </strong>Pulmonary veins isolation (PVI) by cryoballoon (CB) ablation is marginally represented in clinical studies in obese patients. The aim of this analysis was to evaluate the safety and efficacy of CB-PVI in a large cohort of overweight and obese patients from the 1STOP project. <strong>Methods: </strong>From 2012 to 2018, 2048 patients with atrial fibrillation (AF) (70% male, 59 ± 11 years; 75% paroxysmal AF) underwent index CB-PVI. The patient data were separated into three cohorts for statistical evaluation, including: normal weight (body mass index [BMI] &lt; 25 kg/m<sup>2</sup> ), overweight (BMI = 25-30 kg/m<sup>2</sup> ), and obese patients (BMI &gt; 30 kg/m<sup>2</sup> ). <strong>Results: </strong>Out of 2048 patients, 693 (34%) patients had a BMI &lt; 25 and were deemed as normal. There were 944 (46%) patients categorized as overweight (BMI = 25-30) and 411 (20%) as obese (BMI &gt; 30). Overweight or obese patients were more often in persistent AF, had more frequently hypertension and diabetes, had higher CHA<sub>2</sub> DS<sub>2</sub> -VASc score, and had a number of failed antiarrhythmic drug (AAD). Periprocedural complication rates were similar among the three cohorts. The 12-month freedom from AF recurrence was 76.4% in the normal BMI group as compared to 79.2% in the overweight and 73.5% in the obese group (p = .35). However, 48% of overweight patients were on AAD treatment during the follow-up. By multivariate analysis, BMI was not a predictor for AF recurrence following the index CB-PVI. <strong>Conclusion: </strong>CB-PVI in obese patients is a safe procedure. Increased BMI (either moderate or severe) does not seem to be associated with a worse outcome or to a different rate of AAD discontinuation at 12 months.
DOI: 10.5281/zenodo.6337830
title: Dataset related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients"

description: This record contains raw data related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients" <em><strong>Abstract</strong></em> <strong>Background: </strong>Pulmonary veins isolation (PVI) by cryoballoon (CB) ablation is marginally represented in clinical studies in obese patients. The aim of this analysis was to evaluate the safety and efficacy of CB-PVI in a large cohort of overweight and obese patients from the 1STOP project. <strong>Methods: </strong>From 2012 to 2018, 2048 patients with atrial fibrillation (AF) (70% male, 59 ± 11 years; 75% paroxysmal AF) underwent index CB-PVI. The patient data were separated into three cohorts for statistical evaluation, including: normal weight (body mass index [BMI] &lt; 25 kg/m<sup>2</sup> ), overweight (BMI = 25-30 kg/m<sup>2</sup> ), and obese patients (BMI &gt; 30 kg/m<sup>2</sup> ). <strong>Results: </strong>Out of 2048 patients, 693 (34%) patients had a BMI &lt; 25 and were deemed as normal. There were 944 (46%) patients categorized as overweight (BMI = 25-30) and 411 (20%) as obese (BMI &gt; 30). Overweight or obese patients were more often in persistent AF, had more frequently hypertension and diabetes, had higher CHA<sub>2</sub> DS<sub>2</sub> -VASc score, and had a number of failed antiarrhythmic drug (AAD). Periprocedural complication rates were similar among the three cohorts. The 12-month freedom from AF recurrence was 76.4% in the normal BMI group as compared to 79.2% in the overweight and 73.5% in the obese group (p = .35). However, 48% of overweight patients were on AAD treatment during the follow-up. By multivariate analysis, BMI was not a predictor for AF recurrence following the index CB-PVI. <strong>Conclusion: </strong>CB-PVI in obese patients is a safe procedure. Increased BMI (either moderate or severe) does not seem to be associated with a worse outcome or to a different rate of AAD discontinuation at 12 months.
DOI: 10.5281/zenodo.6337500
title: Dataset related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation"

description: This record contains raw data related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation" <em><strong>Abstract</strong></em> <strong>Aims: </strong>Pulmonary vein isolation (PVI) using cryoballoon ablation (CBA) is mainly reserved for patients with drug-refractory or drug-intolerant symptomatic atrial fibrillation. We evaluated a large cohort of patients treated in a real-world setting and examined the safety and efficacy profile of CBA when applied as a first-line treatment for atrial fibrillation. <strong>Methods: </strong>In total, 249 patients (23% women; 56 ± 13 years; mean left atrial diameter 41 ± 7 mm; 73.5% paroxysmal atrial fibrillation; and 26.5% persistent atrial fibrillation) underwent an index PVI by CBA. Data were collected prospectively in the framework of the 1STOP ClinicalService project, involving 26 Italian cardiology centers. <strong>Results: </strong>Median procedure and fluoroscopy times were 90.0 and 21.0 min, respectively. Acute procedural success was 99.8%. Acute/periprocedural complications were observed in seven patients (2.8%), including: four transient diaphragmatic paralyses, one pericardial effusion (not requiring any intervention), one transient ischemic attack, and one minor vascular complication. The Kaplan--Meier freedom from atrial fibrillation recurrence was 86.3% at 12 months and 76% at 24 months. Seventeen patients (6.8%) had a repeat catheter ablation procedure during the follow-up period. At last follow-up, 10% of patients were on an anticoagulation therapy, whereas 6.8% were on an antiarrhythmic drug. <strong>Conclusion: </strong>In our multicenter real-world experience, PVI by CBA in a first-line atrial fibrillation patient population was well tolerated, effective, and promising. CBA with a PVI strategy can be used to treat patients with paroxysmal and persistent atrial fibrillation with good acute procedural success, short procedure times, and acceptable safety. <strong>Clinical trial registration: </strong>clinicaltrials.gov (NCT01007474).
DOI: 10.5281/zenodo.6337499
title: Dataset related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation"

description: This record contains raw data related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation" <em><strong>Abstract</strong></em> <strong>Aims: </strong>Pulmonary vein isolation (PVI) using cryoballoon ablation (CBA) is mainly reserved for patients with drug-refractory or drug-intolerant symptomatic atrial fibrillation. We evaluated a large cohort of patients treated in a real-world setting and examined the safety and efficacy profile of CBA when applied as a first-line treatment for atrial fibrillation. <strong>Methods: </strong>In total, 249 patients (23% women; 56 ± 13 years; mean left atrial diameter 41 ± 7 mm; 73.5% paroxysmal atrial fibrillation; and 26.5% persistent atrial fibrillation) underwent an index PVI by CBA. Data were collected prospectively in the framework of the 1STOP ClinicalService project, involving 26 Italian cardiology centers. <strong>Results: </strong>Median procedure and fluoroscopy times were 90.0 and 21.0 min, respectively. Acute procedural success was 99.8%. Acute/periprocedural complications were observed in seven patients (2.8%), including: four transient diaphragmatic paralyses, one pericardial effusion (not requiring any intervention), one transient ischemic attack, and one minor vascular complication. The Kaplan--Meier freedom from atrial fibrillation recurrence was 86.3% at 12 months and 76% at 24 months. Seventeen patients (6.8%) had a repeat catheter ablation procedure during the follow-up period. At last follow-up, 10% of patients were on an anticoagulation therapy, whereas 6.8% were on an antiarrhythmic drug. <strong>Conclusion: </strong>In our multicenter real-world experience, PVI by CBA in a first-line atrial fibrillation patient population was well tolerated, effective, and promising. CBA with a PVI strategy can be used to treat patients with paroxysmal and persistent atrial fibrillation with good acute procedural success, short procedure times, and acceptable safety. <strong>Clinical trial registration: </strong>clinicaltrials.gov (NCT01007474).
DOI: 10.5517/ccdc.csd.cc8hpq4
title: CCDC 253416: Experimental Crystal Structure Determination

description: Related Article: Cai-Ming Liu|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc95t4d
title: CCDC 273703: Experimental Crystal Structure Determination

description: Related Article: Cai-Ming Liu|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.ccnfc5l
title: CCDC 608659: Experimental Crystal Structure Determination

description: Related Article: Cai-Ming Liu|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.ccnnmkg
title: CCDC 615646: Experimental Crystal Structure Determination

description: Related Article: Cai-Ming Liu|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.ccvy5wt
title: CCDC 802617: Experimental Crystal Structure Determination

description: Related Article: Cai-Ming Liu|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.ccvy5vs
title: CCDC 802616: Experimental Crystal Structure Determination

description: Related Article: Cai-Ming Liu|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc1zy5rv
title: CCDC 1845298: Experimental Crystal Structure Determination

description: Related Article: Zhaojin  Wang|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc20q2jc
title: CSD 1868262: Experimental Crystal Structure Determination

description: Related Article: Patrick Schmidt, Markus Stroebele, H.-Juergen Meyer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc20s0lf
title: CCDC 1870124: Experimental Crystal Structure Determination

description: Related Article: Hee-Seung Lee, Jaewook Kim, Danim Lim|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc23yzvx
title: CSD 1965240: Experimental Crystal Structure Determination

description: Related Article: Patrick Schmidt, Markus Stroebele, Hans-Juergen Meyer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc24ccpl
title: CCDC 1977139: Experimental Crystal Structure Determination

description: Related Article: Lee, Hee-Seung, Kim, Jaewook|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc24p69c
title: CCDC 1986582: Experimental Crystal Structure Determination

description: Related Article: Ming Yan|2021|CSD Communication|||
DOI: 10.5281/zenodo.6337247
title: Dataset related to the article "Key characteristics for effective acute pulmonary vein isolation when using a novel cryoballoon technology: insights from the CHARISMA registry"

description: This record contains raw data related to the article "Key characteristics for effective acute pulmonary vein isolation when using a novel cryoballoon technology: insights from the CHARISMA registry". <em><strong>Abstract</strong></em> <strong>Purpose: </strong>A new cryoballoon (CB) technology (POLARx™; Boston Scientific) for pulmonary vein (PV) isolation in patients with atrial fibrillation (AF) has recently been introduced. The aim of this study was to evaluate procedural and biophysical parameters resulting in acute PV isolation when using this new CB. <strong>Methods: </strong>We assessed the first 69 consecutive patients indicated for AF ablation who underwent PV isolation by means of a novel CB system. Procedural metrics were prospectively recorded. <strong>Results: </strong>A total of 274 PVs were targeted in 69 patients. PV isolation was achieved in all patients by means of cryoablation alone. The median time to isolation (TTI) was 44 [31-68] s (median temperature at TTI = - 49 [- 53 to - 41] °C). The median duration of CB ablation was 180 [180 to 240] s. The median nadir temperature was - 56.0 [- 61 to - 52] °C, and the median thaw time to 0 °C was 18 [15-21] s. The median grade of PV occlusion was 4 [3 to 4]. On the basis of ROC analysis, we defined the following cut-off values for acute PV isolation: - 56 °C for nadir temperature (sensitivity = 73.3%, specificity = 64.6%, AUC = 0.716; positive predictive value = 88.1%), 30 s for TTT (60.2%, 53.3%, 0.578; 79.7%), thaw time &gt; 17 s (65.3%, 70.0%, 0.709; 86.9%), and grade of PV occlusion = 4 (79.4%, 66.7%, 0.738; 88.5%). No major procedure-related adverse events were observed at 30-day post-procedure. <strong>Conclusions: </strong>The new POLARx™ CB appears to be effective and safe. A nadir temperature of - 56 °C, a thaw time to 0 °C ≥ 17 s, and complete PV occlusion were the best predictors of acute PV isolation. <strong>Clinical trial registration: </strong>Catheter Ablation of Arrhythmias with a High-Density Mapping System in Real-World Practice (CHARISMA). URL: http://clinicaltrials.gov/Identifier : NCT03793998. Registration date: January 4, 2019.